Pfizer – Capital Expenditure

Quarterly charts & data from official filings

Timeframe

Capital expenditure

Capital expenditureTable view

Earnings release date
Capital expenditure
Earnings release date:05 May. 26
Capital expenditure:
436,000,000 $-48.4%
Earnings release date:03 Feb. 26
Capital expenditure:
845,000,000 $+40.4%
Earnings release date:04 Nov. 25
Capital expenditure:
602,000,000 $-2.6%
Earnings release date:05 Aug. 25
Capital expenditure:
618,000,000 $+9.6%
Earnings release date:29 Apr. 25
Capital expenditure:
564,000,000 $-38.5%
Earnings release date:04 Feb. 25
Capital expenditure:
917,000,000 $+40.9%
Earnings release date:29 Oct. 24
Capital expenditure:
651,000,000 $+2.2%
Earnings release date:30 Jul. 24
Capital expenditure:
637,000,000 $-9.5%
Earnings release date:01 May. 24
Capital expenditure:
704,000,000 $-32.6%
Earnings release date:30 Jan. 24
Capital expenditure:
1,044,000,000 $+28.9%
Earnings release date:31 Oct. 23
Capital expenditure:
810,000,000 $-11.4%
Earnings release date:01 Aug. 23
Capital expenditure:
914,000,000 $-19.8%
Earnings release date:02 May. 23
Capital expenditure:
1,139,000,000 $+13.8%
Earnings release date:31 Jan. 23
Capital expenditure:
1,001,000,000 $+19.0%
Earnings release date:01 Nov. 22
Capital expenditure:
841,000,000 $+12.0%
Earnings release date:28 Jul. 22
Capital expenditure:
751,000,000 $

Revenue by segment

Revenue by segmentTable view

Earnings release date
Vaccines
Internal Medicine
Hospital
Inflammation & Immunology
Rare Disease
Oncology
Primary Care
Specialty Care
Hospital and Biosimilars
Pfizer CentreOne
Pfizer Ignite
Total
Earnings release date:05 May. 26
Vaccines:
–
Internal Medicine:
–
Hospital:
–
Inflammation & Immunology:
–
Rare Disease:
–
Oncology:
3,826,000,000 $-13.7%
Primary Care:
5,542,000,000 $-30.2%
Specialty Care:
2,939,000,000 $-38.4%
Hospital and Biosimilars:
1,855,000,000 $
Pfizer CentreOne:
289,000,000 $-29.3%
Pfizer Ignite:
–
Total:
14,451,000,000 $-17.7%
Earnings release date:03 Feb. 26
Vaccines:
–
Internal Medicine:
–
Hospital:
–
Inflammation & Immunology:
–
Rare Disease:
–
Oncology:
4,435,000,000 $+4.3%
Primary Care:
7,938,000,000 $+3.8%
Specialty Care:
4,771,000,000 $+8.2%
Hospital and Biosimilars:
–
Pfizer CentreOne:
409,000,000 $+18.9%
Pfizer Ignite:
4,000,000 $
Total:
17,557,000,000 $+5.4%
Earnings release date:04 Nov. 25
Vaccines:
–
Internal Medicine:
–
Hospital:
–
Inflammation & Immunology:
–
Rare Disease:
–
Oncology:
4,253,000,000 $-3.1%
Primary Care:
7,646,000,000 $+38.0%
Specialty Care:
4,411,000,000 $+0.8%
Hospital and Biosimilars:
–
Pfizer CentreOne:
344,000,000 $+4.9%
Pfizer Ignite:
–
Total:
16,654,000,000 $+13.7%
Earnings release date:05 Aug. 25
Vaccines:
–
Internal Medicine:
–
Hospital:
–
Inflammation & Immunology:
–
Rare Disease:
–
Oncology:
4,387,000,000 $+16.7%
Primary Care:
5,540,000,000 $-2.7%
Specialty Care:
4,378,000,000 $+9.8%
Hospital and Biosimilars:
–
Pfizer CentreOne:
328,000,000 $+27.6%
Pfizer Ignite:
20,000,000 $+17.6%
Total:
14,653,000,000 $+6.8%
Earnings release date:29 Apr. 25
Vaccines:
–
Internal Medicine:
–
Hospital:
–
Inflammation & Immunology:
–
Rare Disease:
–
Oncology:
3,758,000,000 $-7.5%
Primary Care:
5,696,000,000 $-36.1%
Specialty Care:
3,987,000,000 $-10.2%
Hospital and Biosimilars:
–
Pfizer CentreOne:
257,000,000 $-20.9%
Pfizer Ignite:
17,000,000 $-34.6%
Total:
13,715,000,000 $-22.8%
Earnings release date:04 Feb. 25
Vaccines:
–
Internal Medicine:
–
Hospital:
–
Inflammation & Immunology:
–
Rare Disease:
–
Oncology:
4,064,000,000 $+0.5%
Primary Care:
8,911,000,000 $-1.6%
Specialty Care:
4,438,000,000 $+3.5%
Hospital and Biosimilars:
–
Pfizer CentreOne:
325,000,000 $+14.0%
Pfizer Ignite:
26,000,000 $+4.0%
Total:
17,764,000,000 $+0.4%
Earnings release date:29 Oct. 24
Vaccines:
–
Internal Medicine:
–
Hospital:
–
Inflammation & Immunology:
–
Rare Disease:
–
Oncology:
4,043,000,000 $+2.2%
Primary Care:
9,060,000,000 $+83.0%
Specialty Care:
4,289,000,000 $+5.0%
Hospital and Biosimilars:
–
Pfizer CentreOne:
285,000,000 $+2.5%
Pfizer Ignite:
25,000,000 $+66.7%
Total:
17,702,000,000 $+33.3%
Earnings release date:30 Jul. 24
Vaccines:
–
Internal Medicine:
–
Hospital:
–
Inflammation & Immunology:
–
Rare Disease:
–
Oncology:
3,956,000,000 $+11.5%
Primary Care:
4,952,000,000 $-31.3%
Specialty Care:
4,083,000,000 $+6.2%
Hospital and Biosimilars:
–
Pfizer CentreOne:
278,000,000 $+7.8%
Pfizer Ignite:
15,000,000 $-11.8%
Total:
13,284,000,000 $-10.7%
Earnings release date:01 May. 24
Vaccines:
–
Internal Medicine:
–
Hospital:
–
Inflammation & Immunology:
–
Rare Disease:
–
Oncology:
3,549,000,000 $+21.0%
Primary Care:
7,211,000,000 $+3.2%
Specialty Care:
3,843,000,000 $-2.7%
Hospital and Biosimilars:
–
Pfizer CentreOne:
258,000,000 $-28.9%
Pfizer Ignite:
17,000,000 $-15.0%
Total:
14,878,000,000 $+4.4%
Earnings release date:30 Jan. 24
Vaccines:
–
Internal Medicine:
–
Hospital:
–
Inflammation & Immunology:
–
Rare Disease:
–
Oncology:
2,932,000,000 $+1.6%
Primary Care:
6,986,000,000 $+11.1%
Specialty Care:
3,949,000,000 $+5.1%
Hospital and Biosimilars:
–
Pfizer CentreOne:
363,000,000 $+24.7%
Pfizer Ignite:
20,000,000 $+100.0%
Total:
14,250,000,000 $+7.7%
Earnings release date:31 Oct. 23
Vaccines:
–
Internal Medicine:
–
Hospital:
–
Inflammation & Immunology:
–
Rare Disease:
–
Oncology:
2,885,000,000 $-2.4%
Primary Care:
6,287,000,000 $+8.2%
Specialty Care:
3,757,000,000 $+2.8%
Hospital and Biosimilars:
–
Pfizer CentreOne:
291,000,000 $-4.9%
Pfizer Ignite:
10,000,000 $+0.0%
Total:
13,230,000,000 $+3.9%
Earnings release date:01 Aug. 23
Vaccines:
–
Internal Medicine:
–
Hospital:
–
Inflammation & Immunology:
–
Rare Disease:
–
Oncology:
2,956,000,000 $+3.5%
Primary Care:
5,810,000,000 $-49.5%
Specialty Care:
3,653,000,000 $+1.1%
Hospital and Biosimilars:
–
Pfizer CentreOne:
306,000,000 $+0.0%
Pfizer Ignite:
10,000,000 $+150.0%
Total:
12,735,000,000 $-30.3%
Earnings release date:02 May. 23
Vaccines:
–
Internal Medicine:
–
Hospital:
–
Inflammation & Immunology:
–
Rare Disease:
–
Oncology:
2,855,000,000 $-5.1%
Primary Care:
11,505,000,000 $-33.7%
Specialty Care:
3,612,000,000 $+1.3%
Hospital and Biosimilars:
–
Pfizer CentreOne:
306,000,000 $-16.8%
Pfizer Ignite:
4,000,000 $
Total:
18,282,000,000 $-24.7%
Earnings release date:31 Jan. 23
Vaccines:
–
Internal Medicine:
–
Hospital:
–
Inflammation & Immunology:
–
Rare Disease:
–
Oncology:
3,007,000,000 $-2.1%
Primary Care:
17,348,000,000 $+9.5%
Specialty Care:
3,566,000,000 $+4.8%
Hospital and Biosimilars:
–
Pfizer CentreOne:
368,000,000 $+15.4%
Pfizer Ignite:
–
Total:
24,289,000,000 $+7.3%
Earnings release date:01 Nov. 22
Vaccines:
–
Internal Medicine:
–
Hospital:
–
Inflammation & Immunology:
–
Rare Disease:
–
Oncology:
3,070,000,000 $-0.6%
Primary Care:
15,846,000,000 $
Specialty Care:
3,404,000,000 $
Hospital and Biosimilars:
–
Pfizer CentreOne:
319,000,000 $+0.6%
Pfizer Ignite:
–
Total:
22,639,000,000 $-18.4%
Earnings release date:28 Jul. 22
Vaccines:
10,459,000,000 $
Internal Medicine:
2,405,000,000 $
Hospital:
9,714,000,000 $
Inflammation & Immunology:
850,000,000 $
Rare Disease:
909,000,000 $
Oncology:
3,088,000,000 $
Primary Care:
–
Specialty Care:
–
Hospital and Biosimilars:
–
Pfizer CentreOne:
317,000,000 $
Pfizer Ignite:
–
Total:
27,742,000,000 $

Operating expenses

Operating expensesTable view

Earnings release date
Cost of sales
Selling, informational and administrative
Research and development
Acquired in-process R&D
Amortization of intangible assets
Restructuring and acquisition-related costs
Total
Earnings release date:05 May. 26
Cost of sales:
3,548,000,000 $-32.7%
Selling, informational and administrative:
2,961,000,000 $-28.9%
Research and development:
2,490,000,000 $-22.3%
Acquired in-process R&D:
137,000,000 $-35.4%
Amortization of intangible assets:
1,183,000,000 $-3.7%
Restructuring and acquisition-related costs:
100,000,000 $-83.4%
Total:
10,419,000,000 $-29.1%
Earnings release date:03 Feb. 26
Cost of sales:
5,272,000,000 $+26.4%
Selling, informational and administrative:
4,162,000,000 $+30.6%
Research and development:
3,206,000,000 $+25.9%
Acquired in-process R&D:
212,000,000 $-84.7%
Amortization of intangible assets:
1,229,000,000 $+0.5%
Restructuring and acquisition-related costs:
604,000,000 $+111.2%
Total:
14,685,000,000 $+14.7%
Earnings release date:04 Nov. 25
Cost of sales:
4,172,000,000 $+10.4%
Selling, informational and administrative:
3,186,000,000 $-6.7%
Research and development:
2,546,000,000 $+2.6%
Acquired in-process R&D:
1,390,000,000 $+69400.0%
Amortization of intangible assets:
1,223,000,000 $+1.0%
Restructuring and acquisition-related costs:
286,000,000 $+1688.9%
Total:
12,803,000,000 $+17.8%
Earnings release date:05 Aug. 25
Cost of sales:
3,778,000,000 $+32.8%
Selling, informational and administrative:
3,415,000,000 $+12.7%
Research and development:
2,482,000,000 $+12.7%
Acquired in-process R&D:
2,000,000 $-77.8%
Amortization of intangible assets:
1,211,000,000 $+0.0%
Restructuring and acquisition-related costs:
-18,000,000 $-102.7%
Total:
10,870,000,000 $+9.0%
Earnings release date:29 Apr. 25
Cost of sales:
2,845,000,000 $-51.9%
Selling, informational and administrative:
3,031,000,000 $-29.1%
Research and development:
2,203,000,000 $-27.4%
Acquired in-process R&D:
9,000,000 $-89.8%
Amortization of intangible assets:
1,211,000,000 $-10.9%
Restructuring and acquisition-related costs:
678,000,000 $-9.6%
Total:
9,977,000,000 $-35.3%
Earnings release date:04 Feb. 25
Cost of sales:
5,909,000,000 $+12.3%
Selling, informational and administrative:
4,274,000,000 $+31.8%
Research and development:
3,035,000,000 $+16.8%
Acquired in-process R&D:
88,000,000 $+576.9%
Amortization of intangible assets:
1,359,000,000 $+3.6%
Restructuring and acquisition-related costs:
750,000,000 $+139.6%
Total:
15,415,000,000 $+21.0%
Earnings release date:29 Oct. 24
Cost of sales:
5,263,000,000 $+59.5%
Selling, informational and administrative:
3,244,000,000 $-12.7%
Research and development:
2,598,000,000 $-3.6%
Acquired in-process R&D:
13,000,000 $+116.7%
Amortization of intangible assets:
1,312,000,000 $+0.4%
Restructuring and acquisition-related costs:
313,000,000 $-75.0%
Total:
12,743,000,000 $+3.8%
Earnings release date:30 Jul. 24
Cost of sales:
3,300,000,000 $-2.3%
Selling, informational and administrative:
3,717,000,000 $+6.4%
Research and development:
2,696,000,000 $+8.1%
Acquired in-process R&D:
6,000,000 $
Amortization of intangible assets:
1,307,000,000 $-0.1%
Restructuring and acquisition-related costs:
1,254,000,000 $+1129.4%
Total:
12,280,000,000 $+13.9%
Earnings release date:01 May. 24
Cost of sales:
3,379,000,000 $-55.3%
Selling, informational and administrative:
3,495,000,000 $-23.6%
Research and development:
2,493,000,000 $-11.4%
Acquired in-process R&D:
–
Amortization of intangible assets:
1,308,000,000 $+3.2%
Restructuring and acquisition-related costs:
102,000,000 $-96.0%
Total:
10,777,000,000 $-42.9%
Earnings release date:30 Jan. 24
Cost of sales:
7,562,000,000 $-18.4%
Selling, informational and administrative:
4,575,000,000 $+39.4%
Research and development:
2,815,000,000 $+3.8%
Acquired in-process R&D:
73,000,000 $+9.0%
Amortization of intangible assets:
1,267,000,000 $+7.5%
Restructuring and acquisition-related costs:
2,566,000,000 $+1555.5%
Total:
18,858,000,000 $+13.2%
Earnings release date:31 Oct. 23
Cost of sales:
9,269,000,000 $+186.3%
Selling, informational and administrative:
3,281,000,000 $-6.2%
Research and development:
2,711,000,000 $+2.4%
Acquired in-process R&D:
67,000,000 $+103.0%
Amortization of intangible assets:
1,179,000,000 $-0.4%
Restructuring and acquisition-related costs:
155,000,000 $-27.6%
Total:
16,662,000,000 $+54.1%
Earnings release date:01 Aug. 23
Cost of sales:
3,237,000,000 $-33.7%
Selling, informational and administrative:
3,497,000,000 $+2.3%
Research and development:
2,648,000,000 $+5.7%
Acquired in-process R&D:
33,000,000 $+57.1%
Amortization of intangible assets:
1,184,000,000 $+7.3%
Restructuring and acquisition-related costs:
214,000,000 $+2277.8%
Total:
10,813,000,000 $-9.5%
Earnings release date:02 May. 23
Cost of sales:
4,886,000,000 $-49.4%
Selling, informational and administrative:
3,418,000,000 $-26.4%
Research and development:
2,505,000,000 $-30.7%
Acquired in-process R&D:
21,000,000 $-71.2%
Amortization of intangible assets:
1,103,000,000 $-2.4%
Restructuring and acquisition-related costs:
9,000,000 $-98.9%
Total:
11,942,000,000 $-40.0%
Earnings release date:31 Jan. 23
Cost of sales:
9,648,000,000 $+59.1%
Selling, informational and administrative:
4,644,000,000 $+37.0%
Research and development:
3,615,000,000 $+34.1%
Acquired in-process R&D:
73,000,000 $-86.1%
Amortization of intangible assets:
1,130,000,000 $+37.5%
Restructuring and acquisition-related costs:
795,000,000 $+299.5%
Total:
19,905,000,000 $+45.3%
Earnings release date:01 Nov. 22
Cost of sales:
6,063,000,000 $-29.9%
Selling, informational and administrative:
3,391,000,000 $+11.3%
Research and development:
2,696,000,000 $-4.2%
Acquired in-process R&D:
524,000,000 $+52300.0%
Amortization of intangible assets:
822,000,000 $+0.0%
Restructuring and acquisition-related costs:
199,000,000 $+5.3%
Total:
13,695,000,000 $-11.8%
Earnings release date:28 Jul. 22
Cost of sales:
8,648,000,000 $
Selling, informational and administrative:
3,048,000,000 $
Research and development:
2,815,000,000 $
Acquired in-process R&D:
1,000,000 $
Amortization of intangible assets:
822,000,000 $
Restructuring and acquisition-related costs:
189,000,000 $
Total:
15,523,000,000 $

Profitability

ProfitabilityTable view

Earnings release date
Net income (shareholders)
Free cash flow
Total
Earnings release date:05 May. 26
Net income (shareholders):
2,687,000,000 $+263.0%
Free cash flow:
2,179,000,000 $-51.6%
Total:
4,866,000,000 $+70.4%
Earnings release date:03 Feb. 26
Net income (shareholders):
-1,648,000,000 $-146.5%
Free cash flow:
4,503,000,000 $+12.5%
Total:
2,855,000,000 $-62.1%
Earnings release date:04 Nov. 25
Net income (shareholders):
3,541,000,000 $+21.7%
Free cash flow:
4,001,000,000 $+433.4%
Total:
7,542,000,000 $+341.1%
Earnings release date:05 Aug. 25
Net income (shareholders):
2,910,000,000 $-1.9%
Free cash flow:
-1,200,000,000 $-167.8%
Total:
1,710,000,000 $-63.9%
Earnings release date:29 Apr. 25
Net income (shareholders):
2,967,000,000 $+623.7%
Free cash flow:
1,771,000,000 $-69.5%
Total:
4,738,000,000 $-23.8%
Earnings release date:04 Feb. 25
Net income (shareholders):
410,000,000 $-90.8%
Free cash flow:
5,804,000,000 $-4.3%
Total:
6,214,000,000 $-41.0%
Earnings release date:29 Oct. 24
Net income (shareholders):
4,465,000,000 $+10790.2%
Free cash flow:
6,063,000,000 $+350.7%
Total:
10,528,000,000 $+542.9%
Earnings release date:30 Jul. 24
Net income (shareholders):
41,000,000 $-98.7%
Free cash flow:
-2,418,000,000 $-726.4%
Total:
-2,377,000,000 $-167.9%
Earnings release date:01 May. 24
Net income (shareholders):
3,115,000,000 $+192.5%
Free cash flow:
386,000,000 $-90.8%
Total:
3,501,000,000 $+323.3%
Earnings release date:30 Jan. 24
Net income (shareholders):
-3,369,000,000 $-41.4%
Free cash flow:
4,196,000,000 $+58.6%
Total:
827,000,000 $+213.3%
Earnings release date:31 Oct. 23
Net income (shareholders):
-2,382,000,000 $-202.4%
Free cash flow:
2,646,000,000 $+224.7%
Total:
264,000,000 $+28.8%
Earnings release date:01 Aug. 23
Net income (shareholders):
2,327,000,000 $-58.0%
Free cash flow:
-2,122,000,000 $-3006.8%
Total:
205,000,000 $-96.3%
Earnings release date:02 May. 23
Net income (shareholders):
5,543,000,000 $+11.0%
Free cash flow:
73,000,000 $-99.0%
Total:
5,616,000,000 $-55.3%
Earnings release date:31 Jan. 23
Net income (shareholders):
4,995,000,000 $-42.0%
Free cash flow:
7,581,000,000 $+47.7%
Total:
12,576,000,000 $-8.5%
Earnings release date:01 Nov. 22
Net income (shareholders):
8,608,000,000 $-13.1%
Free cash flow:
5,133,000,000 $-30.8%
Total:
13,741,000,000 $-20.7%
Earnings release date:28 Jul. 22
Net income (shareholders):
9,906,000,000 $
Free cash flow:
7,419,000,000 $
Total:
17,325,000,000 $

Profit margin in %

Profit margin in %Table view

Earnings release date
Profit margin (shareholders)
Profit margin (free cash flow)
Earnings release date:05 May. 26
Profit margin (shareholders):
18.59 %+28.0 pp
Profit margin (free cash flow):
15.08 %-10.6 pp
Earnings release date:03 Feb. 26
Profit margin (shareholders):
-9.39 %-30.6 pp
Profit margin (free cash flow):
25.65 %+1.6 pp
Earnings release date:04 Nov. 25
Profit margin (shareholders):
21.26 %+1.4 pp
Profit margin (free cash flow):
24.02 %+32.2 pp
Earnings release date:05 Aug. 25
Profit margin (shareholders):
19.86 %-1.8 pp
Profit margin (free cash flow):
-8.19 %-21.1 pp
Earnings release date:29 Apr. 25
Profit margin (shareholders):
21.63 %+19.3 pp
Profit margin (free cash flow):
12.91 %-19.8 pp
Earnings release date:04 Feb. 25
Profit margin (shareholders):
2.31 %-22.9 pp
Profit margin (free cash flow):
32.67 %-1.6 pp
Earnings release date:29 Oct. 24
Profit margin (shareholders):
25.22 %+24.9 pp
Profit margin (free cash flow):
34.25 %+52.5 pp
Earnings release date:30 Jul. 24
Profit margin (shareholders):
0.31 %-20.6 pp
Profit margin (free cash flow):
-18.2 %-20.8 pp
Earnings release date:01 May. 24
Profit margin (shareholders):
20.94 %+44.6 pp
Profit margin (free cash flow):
2.59 %-26.9 pp
Earnings release date:30 Jan. 24
Profit margin (shareholders):
-23.64 %-5.6 pp
Profit margin (free cash flow):
29.45 %+9.4 pp
Earnings release date:31 Oct. 23
Profit margin (shareholders):
-18 %-36.3 pp
Profit margin (free cash flow):
20 %+36.7 pp
Earnings release date:01 Aug. 23
Profit margin (shareholders):
18.27 %-12.0 pp
Profit margin (free cash flow):
-16.66 %-17.1 pp
Earnings release date:02 May. 23
Profit margin (shareholders):
30.32 %+9.8 pp
Profit margin (free cash flow):
0.4 %-30.8 pp
Earnings release date:31 Jan. 23
Profit margin (shareholders):
20.56 %-17.5 pp
Profit margin (free cash flow):
31.21 %+8.5 pp
Earnings release date:01 Nov. 22
Profit margin (shareholders):
38.02 %+2.3 pp
Profit margin (free cash flow):
22.67 %-4.1 pp
Earnings release date:28 Jul. 22
Profit margin (shareholders):
35.71 %
Profit margin (free cash flow):
26.74 %